Advertisement

Topics

Companies Related to "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" [Most Relevant Company Matches] - Page: 2 RSS

19:33 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Immune Tumor Response Multi component Immune Based" Companies 26–50 of 8,100+

Relevant

Northwest Biotherapeutics

Northwest Biotherapeutics (NWBT) is a biotechnology company focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens. Injection of these cells back into the patient initiates a potent immune response against ...


ImmuNext, Inc.

ImmuNext is developing novel therapeutics that modulate the immune system to treat cancer and autoimmune diseases. We are targeting critical immuno-regulatory molecules that either promote or suppress immune responses to restore immune homeostasis and cure disease. Using antibody-based therapeutics and novel recombinant fusion proteins, we are developing a...

Bayhill Therapeutics Inc

Bayhill Thereapeutics is a clinical-stage biopharmaceutical company at the forefront of developing novel and targeted treatment candidates for autoimmune diseases. Leveraging its proprietary therapeutic BHT-DNA™ platform, the Company’s product candidates have been designed to restore the immune system to its normal state, known as “tolerance,”...


Mitra Biotech Inc.

Mitra Biotech, with labs in India and the U.S., is engaged in enabling personalized cancer care and rational drug development through its proprietary pre-clinical platform called CANScriptTM. CANScriptTM is a multi-dimensional platform that can recreate the human tumor microenvironment while maintaining patient tumor heterogeneity, signaling networks and t...

Immune Biosolutions Inc.

Immune Biosolutions (IBio) is an innovative biotech company specialized in the discovery and engineering of chicken humanized antibodies that target proteins with a recognized, yet unexploited, therapeutic potential. Through its Nebula Antibody Platform, Immune Biosolutions generates high-value recombinant antibody portfolios against historically difficult...

Unum Therapeutics

Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and effi...

ENBREL

ENBREL is a type of protein called a tumor necrosis factor (TNF) blocker that blocks the action of a substance your body's immune system makes called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in their bodies. ENBREL can reduce the amount of TNF in the body to normal levels, helping to treat your d...

Quentis Therapeutics

Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy. Based on our deep expertise in endoplasmic reticulum (ER) stress biology and the tumor microenvironment, we are pioneering first-in-class ER stress response modulators t...

Corporate Communications, CEL-SCI Corporation

CEL-SCI Corporation (AMEX: CVM), a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The Company’s core capabilities include drug discovery, research, development and manufacturing of complex biological substances.Recurrence of cancer is the greatest fear for the cancer patient...

Immune Targeting Systems

Immune Targeting Systems is a London based biotech company developing vaccines for mutating viruses based on its broadly applicable next generation DepoVaccine and High Density (HD) Antigen identification technology platforms.

Ultimovacs AS

Ultimovacs AS ('Ultimovacs') was established by Inven2 in 2011. The company's goal is to develop technology from the Norwegian Radium Hospital for use in cancer treatment and to make the treatment available to patients. The technology is based on the possibility of controlling the immune system to make it recognise and kill cancer cells. Ultimovacs is carr...

IDM Pharma

IDM is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer.IDM is currently developing two types of products designed to:• Destroy cancer cells by activating innate immunity• Prevent tumor recurrence by triggering a specific adaptive immune responseOur mission is to provide highly effective treatments that maintain quali...

Orchestra Therapeutics

Orchestra Therapeutics’ unique approach to controlling autoimmune diseases uses small peptide vaccines that appear to stimulate FOXP3+ Regulatory T-cells; a component of the immune system that is now recognized as being key in autoimmune pathogenesis. Rather than disrupting the function of the entire immune system, these therapeutic vaccines are designed to elicit a very specific response – ak...

Serametrix Corporation

Serametrix provides solutions to the problem of monitoring immune response to immunotherapies in clinical trial cancer patients. In partnership with leading institutes Serametrix has developed a suite of immunoassays that monitor anti-tumor immunity in patients enrolled into clinical trials for novel cancer therapies. Serametrix is part owned by the LICR. ...

Cylex, Incorporated

Cylex(TM) is a privately held global life sciences company and a leader in the development and manufacture of research and in vitro diagnostic products intended to assist in the assessment of immune function. Cylex is the first and only company to offer a patent-protected in vitro diagnostic assay (ImmuKnow) used in the detection of cell-mediated immune function in immune-suppressed organ tran...

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics is a privately-held biopharmaceutical company developing immuno-oncology therapies that stimulate the immune system to ‘teach’ it to recognize cancer-specific antigens and attack cancer cells. The company’s patented and proprietary technology platform, called SPIRIT, creates novel therapies that target neoantigens or a...

IFM Therapeutics

IFM Therapeutics is a privately held biopharmaceutical company based in Boston, Massachusetts. The company was founded in 2015 by an international group of preeminent scientists and physicians who have spent decades understanding innate immunity and the role it plays in regulating the immune system. IFM’s team has discovered and developed small molecu...

Lorantis

Lorantis is discovering and developing breakthrough products for the selective treatment of immunological and inflammatory diseases based on immune regulation: the induction of antigen-specific tolerance. Current therapies for immunological and inflammatory diseases either relieve only the symptoms or induce non-specific suppression of the immune system. This can lead to severe infection and drug-...

Biothera, the Immune Health Company

Biothera is a privately held biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer. Its lead cancer drug Imprime PGG is currently in multiple Phase 2 clinical trials for non-small cell lung and in a Phase 3 for colorectal cancer. (www.biothera.com)

ImmunoCellular Therapeutics, Ltd. and BioWa, Inc.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMU...

Jennerex, Inc.

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer -- an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combina...

Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is dedicated to alleviating the burden of patients suffering from autoimmune diseases by developing novel immunotherapeutic agents. Immune's lead product candidate, bertilimumab, is in Phase 2 clinical development for bullous pemphigoid, an orphan autoimmune dermatological condition, and for ulcerative colitis. Oth...

Immune Pharmaceuticals, Inc.

Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Our lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to ...

Progenitor Life Sciences, LLC

Progenitor Life Sciences develops platform solutions for cellular immunotherapy and immune oncology. Our unique proprietary solutions include patented iPSC sourcing and immune-compatibility technology, enabling creation of allogeneic ‘off-the-shelf’ CAR immune cell constructs from a variety of cell sources. Progenitor partners with pharma/biotech...

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. A Phase 1B clinical trial evaluating its oral small molecule checkpoint inhib...


More From BioPortfolio on "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks